Document is current
Any future updates will be listed below
-
Authors
Pérez-Núñez, Iván
Rozalén, Catalina
Palomeque, José Ángel
Sangrador, Irene
Dalmau, Mariona
Comerma, Laura
Hernández-Prat, Anna
Casadevall, David
Menendez, Silvia
Liu, Daniel Dan http://orcid.org/0000-0003-0100-5973
Shen, Minhong
Berenguer, Jordi
Ruiz, Irene Rius http://orcid.org/0000-0002-6097-7572
Peña, Raul
Montañés, José Carlos
Albà, M. Mar
Bonnin, Sarah
Ponomarenko, Julia
Gomis, Roger R. http://orcid.org/0000-0001-6473-2858
Cejalvo, Juan Miguel
Servitja, Sonia
Marzese, Diego M.
Morey, Lluis http://orcid.org/0000-0001-9851-4066
Voorwerk, Leonie
Arribas, Joaquín http://orcid.org/0000-0002-0504-0664
Bermejo, Begoña
Kok, Marleen http://orcid.org/0000-0001-9043-9815
Pusztai, Lajos http://orcid.org/0000-0001-9632-6686
Kang, Yibin http://orcid.org/0000-0002-1626-6730
Albanell, Joan http://orcid.org/0000-0003-1239-4580
Celià-Terrassa, Toni http://orcid.org/0000-0002-0615-8744
- License Information
-
More Information
Article History
Received: 4 February 2021
Accepted: 21 January 2022
First Online: 17 March 2022
Competing interests
: IMIM has filed a patent on the findings based on this study, with T.C.-T., J. Albanell, I.P.-N. and C.R. are named as coinventors. J. Albanell has received consulting fees and honoraria from Seagen, Pfizer, AstraZeneca, Lilly, Merck, Roche, Gilead, Novartis and Daiichi-Sankyo, receives royalties from a licensed patent to Biocartis and holds stock options from Inbiomotion. J. Arribas reports grants from Roche, Synthon/Biondys and Molecular Partners; and grants and personal fees from Menarini and Mnemo during the conduct of the study. J. Arribas has a patent for EP 0930183.5 issued, licensed and with royalties paid, a patent for P200801652 issued, licensed and with royalties paid, and a patent for EP20382457.8 pending, licensed and with royalties paid. L.C. reports being an advisory board member and receiving honoraria as speaker’s bureau from Roche. L.P. has received consulting fees and honoraria from Seagen, Pfizer, Astra Zeneca, Merck, Novartis, Bristol Myers Squibb, Genentech, Eisai, Pieris, Immunomedics, Clovis, Syndax, H3Bio, Radius Health, Personalis, Natera and Daiichi; and institutional research funding from Seagen, AstraZeneca, Merck, Pfizer and Bristol Myers Squibb. The remaining authors declare no competing interest.
Free to read: This content has been made available to all.
